专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明公开

EP3332814A1 CELL STRUCTURE, NON-HUMAN MODEL ANIMAL, METHOD FOR PRODUCING NON-HUMAN MODEL ANIMAL, AND METHOD FOR EVALUATING TEST SUBSTANCE 审中-公开
公开(公告)号：EP3332814A1
公开(公告)日：2018-06-13
申请号：EP16832892.0
申请日：2016-07-28
申请人： FUJIFILM Corporation
发明人： NAKAMURA, Kentaro , MIMA, Shinji , KITAHASHI, Tsukasa , KAKINUMA, Chihaya
IPC分类号： A61L27/00 , A61K35/13 , A61K35/28 , A61P35/00 , A61P37/04 , C12N5/077 , C12N5/09 , G01N33/15 , G01N33/50
CPC分类号： C12N11/02 , A01K67/0271 , A01K2207/12 , A01K2207/15 , A01K2207/30 , A01K2227/105 , A01K2267/0331 , A61K35/13 , A61K35/28 , A61K49/0008 , A61L27/00 , C12N5/0695 , C12N2533/54 , G01N33/50
摘要： An object of the present invention is to provide a non-human model animal rich in stromal tissue, a cell structure useful for producing the above-described non-human model animal, a method for evaluating a test substance in which the above-described non-human model animal is used, and a method for producing the above-described non-human model animal. According to the present invention, a cell structure is provided which contains a biocompatible macromolecular block and at least a cancer cell and a mesenchymal cell, and in which a plurality of the above-described biocompatible macromolecular blocks are arranged in gaps between a plurality of the above-described cells.

2. 发明授权

EP2343080B1 PHARMACEUTICAL COMPOSITION FOR TREATING BONE DISEASES WHICH COMPRISES PROTEIN COMPRISING Frizzled1, Frizzled2 OR Frizzled7 EXTRACELLULAR CYSTEINE-RICH DOMAIN AND Fc PROTEIN 有权
标题翻译：药物组合物治疗骨疾病，包括蛋白质，它包含卷曲蛋白，Frizzled2或Frizzled7外半胱氨酸富含结构域和Fc蛋白
公开(公告)号：EP2343080B1
公开(公告)日：2017-11-08
申请号：EP09817788.4
申请日：2009-09-30
申请人： Kyowa Hakko Kirin Co., Ltd.
发明人： KAKITANI, Makoto , TOMIZUKA, Kazuma
IPC分类号： A61K38/00 , A61K48/00 , A61P19/08 , A61P19/10
CPC分类号： A61K38/177 , A01K67/027 , A01K67/0271 , A01K2207/12 , A01K2207/30 , A01K2217/072 , A01K2227/105 , A01K2267/035 , A61K31/7088 , A61K38/1709 , A61K39/3955 , A61K45/06 , A61K47/60 , A61K47/6835 , A61K48/00 , C07K14/723 , C07K2319/30
摘要： This invention relates to a pharmaceutical composition for treatment of a bone disease comprising, as an active ingredient, a protein comprising an extracellular cysteine-rich domain, which is from the Frizzled receptor selected from the group consisting of mammalian animal-derived Frizzled 1, Frizzled 2, and Frizzled 7 and has activity of increasing bone mass, bone density, and/or bone strength, or a mutant of such domain having sequence identity of 85% or higher to the amino acid sequence of the domain and having activity of increasing bone mass, bone density, and/or bone strength, or a vector comprising a nucleic acid encoding the protein.

3. 发明授权

EP2182969B1 A MICRO-RNA FAMILY THAT MODULATES FIBROSIS AND USES THEREOF 有权
标题翻译： miRNA家族AS调制器纤维化及其用途
公开(公告)号：EP2182969B1
公开(公告)日：2016-11-16
申请号：EP08797006.7
申请日：2008-07-31
申请人： The Board of Regents of The University of Texas System
发明人： OLSON, Eric , VAN ROOIJ, Eva
IPC分类号： C12N15/113 , A61P9/00 , A61K31/712 , A61K31/713 , A61F2/07 , A61Q19/00
CPC分类号： C12N15/113 , A01K67/0276 , A01K2207/30 , A01K2217/052 , A01K2217/075 , A01K2217/15 , A01K2217/206 , A01K2227/105 , A01K2267/0375 , A61K31/07 , A61K31/355 , A61K31/375 , A61K31/7105 , A61K31/712 , A61K31/7125 , A61K31/713 , A61K38/2242 , A61K39/3955 , A61K45/06 , A61L31/08 , A61L31/16 , A61L2300/258 , A61L2300/45 , A61L2420/06 , C12N9/16 , C12N15/8509 , C12N2310/113 , C12N2310/141 , C12N2310/315 , C12N2310/321 , C12N2310/346 , C12N2310/3515 , C12N2310/3521 , C12N2320/30 , C12N2320/31 , C12N2320/32 , C12N2330/10 , G06F19/00 , Y02A90/26 , A61K2300/00
摘要： The present invention relates to the identification of a microRNA family, designated miR-29a-c, that is a key regulator of fibrosis in cardiac tissue. The inventors show that members of the miR-29 family are down-regulated in the heart tissue in response to stress, and are up-regulated in heart tissue of mice that are resistant to both stress and fibrosis. Also provided are methods of modulating expression and activity of the miR-29 family of miRNAs as a treatment for fibrotic disease, including cardiac hypertrophy, skeletal muscle fibrosis other fibrosis related diseases and collagen loss-related disease.

4. 发明公开

EP2773382A1 CO-ACTIVATION OF MTOR AND STAT3 PATHWAYS TO PROMOTE NEURONAL SURVIVAL AND REGENERATION 审中-公开
标题翻译：作者mTOR和STAT3 PATHS同时激活促进神经元存活和再生
公开(公告)号：EP2773382A1
公开(公告)日：2014-09-10
申请号：EP12845212.5
申请日：2012-11-01
申请人： Children's Medical Center Corporation , He, Zhigang , Jin, Duo , Sun, Fang
发明人： HE, Zhigang , JIN, Duo , SUN, Fang
IPC分类号： A61K48/00 , A61K31/44 , A61P25/00
CPC分类号： A61K38/1709 , A01K67/0276 , A01K2207/30 , A01K2217/075 , A01K2217/15 , A01K2217/206 , A01K2227/105 , A01K2267/0356 , A61K9/0085 , A61K31/11 , A61K31/196 , A61K31/4353 , A61K31/444 , A61K31/555 , A61K31/708 , A61K31/7088 , A61K31/713 , A61K33/24 , A61K39/39533 , A61K45/06 , C07K14/4703 , C12N9/16 , C12Y301/03048 , A61K2300/00
摘要： Disclosed herein is a method of promoting sustained survival, sustained regeneration, in a lesioned mature neuron, sustained compensatory outgrowth in a neuron, or combinations thereof. The method comprises contacting the lesioned mature neuron with an effective amount of an inhibitor of PTEN and an effective amount of an inhibitor of SOCS3 to thereby promote survival and/or regeneration and/or compensatory outgrowth of the neuron. Therapeutic methods of treatment of a subject with a neuronal lesion by administration of a therapeutically effective amount of an inhibitor of PTEN and a therapeutically effective amount of an inhibitor of SOCS3, are also disclosed, as are pharmaceutical compositions and devices for use in the methods.

5. 发明公开

EP2403937A2 METHODS OF INHIBITING PHOTORECEPTOR APOPTOSIS 有权
标题翻译：使用MET肽公关抑制凋亡的
公开(公告)号：EP2403937A2
公开(公告)日：2012-01-11
申请号：EP10749294.4
申请日：2010-03-03
申请人： The Regents of the University of Michigan
发明人： ZACKS, David Noam
IPC分类号： C12N5/02 , C07K14/54 , A61K38/20 , A61P27/02
CPC分类号： A61K38/204 , A01K67/027 , A01K2207/30 , A01K2227/105 , A01K2267/035 , A61K9/0048 , A61K38/00 , A61K38/08 , A61K38/10 , A61K38/1761 , A61K38/179 , A61K48/00 , C07K14/4703 , C07K14/5412 , C12N2799/025
摘要： The present invention provides methods to prevent photoreceptor death. In particular, the present invention provides peptides which prevent FAS-mediated photoreceptor apoptosis.

6. 发明授权

EP2193204B1 COMPOSITIONS COMPRENANT DES LIPOPHOSPHORAMIDES ET LEURS UTILISATIONS EN THERAPIE GENIQUE 有权
标题翻译： LIPOPHOSPHORAMIDE含筹备工作及其用途的基因治疗
公开(公告)号：EP2193204B1
公开(公告)日：2011-08-31
申请号：EP08839001.8
申请日：2008-09-25
申请人： Universite de Bretagne Occidentale , Centre National de la Recherche Scientifique
发明人： CLEMENT, Jean-Claude , PICHON, Harivony , MIDOUX, Patrick , YAOUANC, Jean-Jacques , MEVEL, Mathieu
IPC分类号： C12N15/88 , A61K48/00 , A61K47/24 , A61K31/664 , A61K45/06 , C07F9/22 , A61K31/7084
CPC分类号： A61K31/664 , A01K2207/30 , A01K2227/105 , A01K2267/03 , A61K9/1272 , A61K31/7084 , A61K48/00 , C07F9/2458 , C07F9/65061 , C07F9/65067 , C12N15/88
摘要： The invention relates to novel co-lipids that can be used in combination with lipophilic compounds used as nucleic acid vectors, for making a nucleic-acid vector composition. The invention also relates to nucleic-acid vector compositions containing a combination of (i) a nucleic-acid cationic lipohilic vector and (ii) a co-lipid. In some embodiments, the nucleic-acid vector compositions are in the form of unilamellar or multilamellar vesicles. The invention also relates to a method for the in vitro or in vivo insertion of a nucleic acid of interest into host cells, that comprises the step of contacting said host cells with a nucleic-acid vector composition as described above.

7. 发明公开

EP2046349A4 TREATMENT OF EXCESSIVE NEOVASCULARIZATION 有权
标题翻译：过度治疗新生血管
公开(公告)号：EP2046349A4
公开(公告)日：2010-11-10
申请号：EP07784641
申请日：2007-07-12
申请人： ANGIOBLAST SYSTEMS INC
发明人： RAKOCZY PIROSKA ELIZABETH
IPC分类号： A61K35/28 , A61P1/00 , A61P7/04 , A61P9/00 , A61P9/10 , A61P17/00 , A61P17/06 , A61P19/02 , A61P27/02 , A61P31/04 , A61P35/00 , C12N5/0775
CPC分类号： A61K35/28 , A01K67/027 , A01K2207/30 , A01K2227/105 , A01K2267/0375 , A01K2267/0393 , A61K2035/124 , C12N5/0663
摘要： The present invention relates to methods of treating or preventing angiogenesis-related diseases by the administration of stem cells and/or progeny cells thereof.

8. 发明公开

EP2139314A2 ANIMAL MODEL, SYSTEM, AND METHOD FOR SCREENING COMPOUNDS FOR ANTITHROMBOTIC AND/OR THROMBOLYTIC ACTIVITY 审中-公开
标题翻译：用于筛选抗血栓和/或溶栓活性化合物的动物模型，系统和方法
公开(公告)号：EP2139314A2
公开(公告)日：2010-01-06
申请号：EP08719743.0
申请日：2008-03-18
申请人： Piramal Life Sciences Limited
发明人： GUPTE, Ravindra, Dattatraya , TANNU, Aditi, Amol , PANICKER, Radha, Bhaskar , SHARMA, Somesh
IPC分类号： A01K67/027
CPC分类号： A01K67/027 , A01K2207/30 , A01K2207/35 , A01K2227/105 , A01K2267/035
摘要： The present invention relates to a method for evaluating a test compound for antithrombotic activity, thrombolytic activity, or a combination thereof. This method can include providing or employing a donor test animal and a recipient test animal. The donor and recipient test animals can have been pretreated with test compound. The donor test animal can be configured to provide oxygenated blood to the recipient test animal through a thrombus inducing system. This method also includes initiating transport of blood from the donor test animal to the recipient test animal through the thrombus inducing system. The method can include interrupting respiration of the recipient test animal and determining the length of time that the recipient test animal survives. In this method, a survival time longer than a predetermined threshold time indicates that the test compound has antithrombotic activity, thrombolytic activity, or a combination thereof.
摘要翻译：本发明涉及用于评估测试化合物的抗血栓形成活性，血栓溶解活性或其组合的方法。该方法可以包括提供或采用供体测试动物和受体测试动物。供体和受体测试动物可以用测试化合物预处理。供体测试动物可以被配置成通过血栓诱导系统向接受者测试动物提供含氧血液。该方法还包括通过血栓诱导系统开始将血液从供体试验动物输送至受体试验动物。该方法可以包括中断接受者测试动物的呼吸并且确定接受者测试动物存活的时间长度。在该方法中，比预定的阈值时间更长的存活时间表明测试化合物具有抗血栓形成活性，血栓溶解活性或其组合。

9. 发明公开

EP3060653A1 METHOD FOR REDUCING THE INFLAMMATORY ACTIVITY OF A STEM CELL TRANSPLANT AND USE THEREOF 审中-公开
标题翻译：一种用于减少干细胞移植物和使用点火其活性
公开(公告)号：EP3060653A1
公开(公告)日：2016-08-31
申请号：EP14789278.0
申请日：2014-10-24
申请人： Neuroplast Beheer B.V.
发明人： MUNTER, DE, Johannes Petrus Jozef Maria , LANG, Ekkehard , WOLTERS, Erik Charles Marie Joseph , HAAN, DE, Petrus Theodorus
IPC分类号： C12N5/0775 , C12N5/0789 , A61K35/12 , A61K35/16 , A01K67/027
CPC分类号： A61K35/28 , A01K67/0271 , A01K2207/30 , A01K2227/105 , A01K2267/0356 , A01K2267/0368 , A61K35/16 , A61K38/1722 , A61K2035/124 , C12N5/0087 , C12N5/0647 , C12N5/0663 , C12N2533/56 , A61K2300/00
摘要： The disclosure is in the field of cell therapy, more in particular, stem cell transplantation therapy. The disclosure provides methods and compositions for improving the efficacy of stem cell transplantation therapy by reducing the inflammatory activity of a stem cell transplant. More in particular, the disclosure provides a method for preparing a stem cell transplant with reduced inflammatory activity comprising a step of suspending a composition comprising stem cells in a fibrinogen-depleted plasma and/or in a fibrinogen and C-reactive protein-depleted plasma.

10. 发明公开

EP2939534A1 Animal model for Parkes-Weber syndrome 有权
标题翻译： TiermodellfürParkes Weber Syndrom
公开(公告)号：EP2939534A1
公开(公告)日：2015-11-04
申请号：EP14001527.2
申请日：2014-04-30
申请人： Warszawski Uniwersytet Medyczny , INSTYTUT FARMACEUTYCZNY
发明人： Koziak, Katarzyna , Bojakowski, Krzysztof , Kowalewska, Magdalena , Maciejko, Dorota , Zegrocka-Stendel, Oliwia , Grabowska, Iwona , Surowiecka, Agnieszka
IPC分类号： A01K67/027 , A61K36/77
CPC分类号： A01K67/027 , A01K2207/30 , A01K2227/105 , A01K2267/0306 , A01K2267/0375
摘要： A non-human animal mammalian model for Parkes-Weber syndrome, wherein an animal has an arteriovenous fistula and a venous ligature in at least one of the limbs, is provided. The invention also relates to a method for preparing the model. The desired model reflects the pathophysiological characteristics of PW syndrome and can be used in studies on PW syndrome, including etiology of the syndrome. The animal model can also be used for screening a material for vascular use and for screening a preventive and/or therapeutic agent for Parkes-Weber syndrome.
摘要翻译：提供了一种用于Parkes-Weber综合征的非人动物哺乳动物模型，其中动物在至少一个肢体中具有动静脉瘘和静脉结扎。本发明还涉及一种用于制备该模型的方法。所需模型反映了PW综合征的病理生理特征，可用于PW综合征的研究，包括综合征病因。动物模型也可用于筛选用于血管使用的材料和筛选Parkes-Weber综合征的预防和/或治疗剂。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式